RDH8
geneOn this page
Also known as PRRDHSDR28C2
Summary
RDH8 (retinol dehydrogenase 8, HGNC:14423) is a protein-coding gene on chromosome 19p13.2, encoding Retinol dehydrogenase 8 (Q9NYR8). Retinol dehydrogenase with a clear preference for NADP.
This gene encodes a member of the short-chain dehydrogenase/reductase family. The encoded protein catalyzes the reduction of all-trans-retinal to all-trans-retinol, the first reaction step of the rhodopsin regeneration pathway. This enzymatic reaction is the rate-limiting step in the visual cycle.
Source: NCBI Gene 50700 — RefSeq curated summary.
At a glance
- GWAS associations: 1
- Clinical variants (ClinVar): 28 total — 1 pathogenic
- Phenotypes (HPO): 10
- MANE Select transcript:
NM_015725
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:14423 |
| Approved symbol | RDH8 |
| Name | retinol dehydrogenase 8 |
| Location | 19p13.2 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | PRRDH, SDR28C2 |
| Ensembl gene | ENSG00000080511 |
| Ensembl biotype | protein_coding |
| OMIM | 608575 |
| Entrez | 50700 |
Gene structure
Transcript identifiers
Ensembl transcripts: 4 — 3 protein_coding, 1 retained_intron
ENST00000587782, ENST00000589570, ENST00000591589, ENST00000651512
RefSeq mRNA: 1 — MANE Select: NM_015725
NM_015725
CCDS: CCDS12223
Canonical transcript exons
ENST00000591589 — 6 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000675840 | 10017057 | 10017215 |
| ENSE00000675841 | 10018731 | 10018910 |
| ENSE00000675842 | 10020709 | 10020802 |
| ENSE00001188705 | 10021255 | 10021438 |
| ENSE00002806681 | 10021534 | 10022279 |
| ENSE00003893086 | 10013483 | 10013600 |
Expression profiles
Bgee: expression breadth broad, 64 present calls, max score 76.52.
FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.0776 / max 36.1013, expressed in 15 samples.
FANTOM5 promoters (2 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 173711 | 0.0705 | 15 |
| 173712 | 0.0071 | 3 |
Top tissues by expression
202 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| sperm | CL:0000019 | 76.52 | gold quality |
| myocardium | UBERON:0002349 | 73.22 | gold quality |
| vena cava | UBERON:0004087 | 68.69 | gold quality |
| metanephros cortex | UBERON:0010533 | 68.11 | gold quality |
| lateral nuclear group of thalamus | UBERON:0002736 | 66.67 | gold quality |
| body of tongue | UBERON:0011876 | 66.53 | gold quality |
| periodontal ligament | UBERON:0008266 | 66.51 | gold quality |
| subthalamic nucleus | UBERON:0001906 | 66.46 | gold quality |
| pharyngeal mucosa | UBERON:0000355 | 66.31 | gold quality |
| pericardium | UBERON:0002407 | 66.31 | gold quality |
| dorsal plus ventral thalamus | UBERON:0001897 | 66.13 | gold quality |
| right testis | UBERON:0004534 | 65.97 | gold quality |
| saphenous vein | UBERON:0007318 | 65.74 | gold quality |
| cardia of stomach | UBERON:0001162 | 65.68 | gold quality |
| inferior vagus X ganglion | UBERON:0005363 | 65.66 | gold quality |
| tongue | UBERON:0001723 | 65.62 | gold quality |
| secondary oocyte | CL:0000655 | 65.31 | gold quality |
| thymus | UBERON:0002370 | 65.21 | gold quality |
| superior surface of tongue | UBERON:0007371 | 65.20 | gold quality |
| superior vestibular nucleus | UBERON:0007227 | 65.08 | gold quality |
| nipple | UBERON:0002030 | 65.03 | gold quality |
| substantia nigra pars reticulata | UBERON:0001966 | 64.96 | gold quality |
| ventral tegmental area | UBERON:0002691 | 64.89 | gold quality |
| cerebellar vermis | UBERON:0004720 | 64.84 | gold quality |
| substantia nigra pars compacta | UBERON:0001965 | 64.82 | gold quality |
| pons | UBERON:0000988 | 64.79 | gold quality |
| lateral globus pallidus | UBERON:0002476 | 64.79 | gold quality |
| trachea | UBERON:0003126 | 64.66 | gold quality |
| synovial joint | UBERON:0002217 | 64.58 | gold quality |
| layer of synovial tissue | UBERON:0007616 | 64.56 | gold quality |
Single-cell (SCXA)
Detected in 2 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-MTAB-7316 | no | 29.21 |
| E-ANND-3 | no | 1.96 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
24 targeting RDH8, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-1277-5P | 100.00 | 73.95 | 5056 |
| HSA-MIR-190A-3P | 100.00 | 80.35 | 5520 |
| HSA-MIR-5011-5P | 100.00 | 83.46 | 5820 |
| HSA-MIR-6867-5P | 100.00 | 82.21 | 3464 |
| HSA-MIR-4534 | 99.99 | 66.58 | 1907 |
| HSA-MIR-3148 | 99.97 | 75.06 | 6478 |
| HSA-MIR-3688-3P | 99.97 | 72.02 | 2834 |
| HSA-MIR-8075 | 99.97 | 67.20 | 962 |
| HSA-MIR-7978 | 99.86 | 66.90 | 856 |
| HSA-MIR-1287-3P | 99.63 | 66.93 | 492 |
| HSA-MIR-183-3P | 99.41 | 69.41 | 1598 |
| HSA-MIR-5582-5P | 99.27 | 71.42 | 1879 |
| HSA-MIR-4709-3P | 98.88 | 68.04 | 1594 |
| HSA-MIR-6840-3P | 98.68 | 65.95 | 1923 |
| HSA-MIR-8060 | 98.61 | 66.93 | 1187 |
| HSA-MIR-138-5P | 98.43 | 70.49 | 1292 |
| HSA-MIR-4294 | 97.86 | 65.72 | 1110 |
| HSA-MIR-3121-5P | 97.30 | 66.62 | 1146 |
| HSA-MIR-122-5P | 97.23 | 64.92 | 1024 |
| HSA-MIR-12128 | 96.67 | 66.98 | 1471 |
| HSA-MIR-4491 | 96.53 | 66.20 | 935 |
| HSA-MIR-4657 | 96.53 | 66.57 | 895 |
| HSA-MIR-576-3P | 96.14 | 65.63 | 773 |
| HSA-MIR-6846-3P | 94.80 | 65.19 | 389 |
Literature-anchored findings (GeneRIF, showing 5)
- prRDH is an enzyme that catalyzes reduction of all-trans-retinal in the rod outer segment, most noticeably at higher light intensities and prolonged illumination, but is not an essential enzyme of the retinoid cycle (PMID:15755727)
- Our family- and population-based data both suggest that the RDH8 gene is unlikely to be associated with high myopia in Chinese (PMID:21043051)
- Progression of retinal degeneration in Rdh8-deficient Abca4-deficient mice is affected by differential vulnerability of rods and cones to light. (PMID:22220722)
- Targeted capture sequencing identifies genetic variations of GRK4 and RDH8 in Han Chinese with essential hypertension in Xinjiang. (PMID:34297769)
- A Splicing Variant in RDH8 Is Associated with Autosomal Recessive Stargardt Macular Dystrophy. (PMID:37628710)
Cross-species orthologs
17 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | rdh8a | ENSDARG00000028048 |
| danio_rerio | RDH8 | ENSDARG00000099217 |
| danio_rerio | rdh8b | ENSDARG00000105060 |
| mus_musculus | Rdh8 | ENSMUSG00000053773 |
| rattus_norvegicus | Rdh8 | ENSRNOG00000025767 |
| drosophila_melanogaster | CG7601 | FBGN0027583 |
| drosophila_melanogaster | CG31546 | FBGN0051546 |
| drosophila_melanogaster | CG31548 | FBGN0051548 |
| caenorhabditis_elegans | WBGENE00000970 | |
| caenorhabditis_elegans | WBGENE00000975 | |
| caenorhabditis_elegans | WBGENE00000981 | |
| caenorhabditis_elegans | WBGENE00000993 | |
| caenorhabditis_elegans | WBGENE00008985 | |
| caenorhabditis_elegans | WBGENE00008986 | |
| caenorhabditis_elegans | WBGENE00011424 | |
| caenorhabditis_elegans | WBGENE00022809 | |
| caenorhabditis_elegans | WBGENE00219274 |
Paralogs (13): DHRS7 (ENSG00000100612), DHRS2 (ENSG00000100867), DHRS7B (ENSG00000109016), HSD11B1 (ENSG00000117594), HSDL2 (ENSG00000119471), DHRS4 (ENSG00000157326), DHRS1 (ENSG00000157379), CBR1 (ENSG00000159228), CBR3 (ENSG00000159231), HSD11B1L (ENSG00000167733), DHRS7C (ENSG00000184544), DHRS4L2 (ENSG00000187630), DHRS11 (ENSG00000278535)
Protein
Protein identifiers
Retinol dehydrogenase 8 — Q9NYR8 (reviewed: Q9NYR8)
Alternative names: Photoreceptor outer segment all-trans retinol dehydrogenase, Short chain dehydrogenase/reductase family 28C member 2
All UniProt accessions (3): Q9NYR8, K7EKT5, K7ELF7
UniProt curated annotations — full annotation on UniProt →
Function. Retinol dehydrogenase with a clear preference for NADP. Converts all-trans-retinal to all-trans-retinol. May play a role in the regeneration of visual pigment at high light intensity.
Subcellular location. Membrane.
Tissue specificity. Detected in photoreceptor outer segments in the retina (at protein level).
Disease relevance. Stargardt disease 5 (STGD5) [MIM:621259] A form of Stargardt disease, a common hereditary macular degeneration characterized by decreased central vision, atrophy of the macula and underlying retinal pigment epithelium, and frequent presence of prominent flecks in the posterior pole of the retina. STGD5 is an autosomal recessive form characterized by onset of macular dystrophy in the fifth decade of life. The disease is caused by variants affecting the gene represented in this entry.
Similarity. Belongs to the short-chain dehydrogenases/reductases (SDR) family.
RefSeq proteins (1): NP_056540* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR002347 | SDR_fam | Family |
| IPR011348 | 17beta_DH | Family |
| IPR020904 | Sc_DH/Rdtase_CS | Conserved_site |
| IPR036291 | NAD(P)-bd_dom_sf | Homologous_superfamily |
Pfam: PF00106
Enzyme classification (BRENDA):
- EC 1.1.1.300 — NADP-retinol dehydrogenase (BRENDA: 11 organisms, 101 substrates, 7 inhibitors, 67 Km, 12 kcat entries)
Substrate kinetics (BRENDA)
14 substrates with measured Km, best-characterized 14. Km ranges are aggregated across organisms/conditions.
| Substrate | Km (mM) | Measurements |
|---|---|---|
| ALL-TRANS-RETINAL | 0.0001–0.5 | 19 |
| NADPH | 0.0005–0.23 | 10 |
| NADP+ | 0.0004–0.8 | 9 |
| ALL-TRANS-RETINOL | 0.0006–1.3 | 6 |
| NADH | 2.22–1300 | 4 |
| ALL-TRANS-3-HYDROXYRETINAL | 0.0032–0.0044 | 3 |
| ESTRONE | 0.0096–0.0307 | 3 |
| NAD+ | 0.004–680 | 3 |
| 9-CIS-RETINAL | 0.0001–0.19 | 2 |
| RETINAL | 0.007–0.13 | 2 |
| 11-CIS-RETINAL | 0.0001 | 1 |
| 11-CIS-RETINOL | 0.0016 | 1 |
| 13-CIS-RETINAL | 0.62 | 1 |
| 9-CIS-RETINOL | 0.0016 | 1 |
Catalyzed reactions (Rhea), 1 shown:
- all-trans-retinol + NADP(+) = all-trans-retinal + NADPH + H(+) (RHEA:25033)
UniProt features (9 total): transmembrane region 3, binding site 2, sequence variant 2, chain 1, active site 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q9NYR8-F1 | 92.68 | 0.76 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Catalytic / active sites (1): 155 (proton acceptor)
Ligand- & substrate-binding residues (2): 9–18; 142
Function
Pathways and Gene Ontology
Reactome pathways
1 pathways
| ID | Pathway |
|---|---|
| R-HSA-2453902 | The canonical retinoid cycle in rods (twilight vision) |
MSigDB gene sets: 54 (showing top):
GOBP_REGULATION_OF_HORMONE_LEVELS, GOBP_RETINOL_METABOLIC_PROCESS, GOMF_STEROID_DEHYDROGENASE_ACTIVITY_ACTING_ON_THE_CH_OH_GROUP_OF_DONORS_NAD_OR_NADP_AS_ACCEPTOR, GOBP_SENSORY_PERCEPTION_OF_LIGHT_STIMULUS, GOBP_HORMONE_BIOSYNTHETIC_PROCESS, GOBP_STEROID_BIOSYNTHETIC_PROCESS, GOBP_LIPID_METABOLIC_PROCESS, GOBP_LIPID_BIOSYNTHETIC_PROCESS, GOBP_SENSORY_PERCEPTION, GOBP_ESTROGEN_BIOSYNTHETIC_PROCESS, GOMF_OXIDOREDUCTASE_ACTIVITY_ACTING_ON_CH_OH_GROUP_OF_DONORS, GOBP_ISOPRENOID_METABOLIC_PROCESS, GOBP_PRIMARY_ALCOHOL_METABOLIC_PROCESS, GOBP_ESTROGEN_METABOLIC_PROCESS, GOBP_STEROID_METABOLIC_PROCESS
GO Biological Process (5): steroid biosynthetic process (GO:0006694), estrogen biosynthetic process (GO:0006703), visual perception (GO:0007601), retinol metabolic process (GO:0042572), lipid metabolic process (GO:0006629)
GO Molecular Function (4): estradiol 17-beta-dehydrogenase [NAD(P)+] activity (GO:0004303), all-trans-retinol dehydrogenase (NAD+) activity (GO:0004745), all-trans-retinol dehydrogenase (NADP+) activity (GO:0052650), oxidoreductase activity (GO:0016491)
GO Cellular Component (4): cytosol (GO:0005829), plasma membrane (GO:0005886), cytoplasm (GO:0005737), membrane (GO:0016020)
Reactome top-level categories
Rollup of top-1 pathways:
| Category | Pathways |
|---|---|
| Visual phototransduction | 1 |
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cellular anatomical structure | 3 |
| steroid metabolic process | 1 |
| lipid biosynthetic process | 1 |
| estrogen metabolic process | 1 |
| hormone biosynthetic process | 1 |
| steroid hormone biosynthetic process | 1 |
| sensory perception of light stimulus | 1 |
| retinoid metabolic process | 1 |
| primary alcohol metabolic process | 1 |
| hormone metabolic process | 1 |
| olefinic compound metabolic process | 1 |
| primary metabolic process | 1 |
| steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor | 1 |
| alcohol dehydrogenase (NAD+) activity | 1 |
| alcohol dehydrogenase (NADP+) activity | 1 |
| retinol metabolic process | 1 |
| catalytic activity | 1 |
| cytoplasm | 1 |
| membrane | 1 |
| cell periphery | 1 |
| intracellular anatomical structure | 1 |
Protein interactions and networks
STRING
2975 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| RDH8 | RLBP1 | P12271 | 891 |
| RDH8 | RHO | P08100 | 803 |
| RDH8 | ABCA4 | P78363 | 786 |
| RDH8 | RDH12 | Q96NR8 | 727 |
| RDH8 | RDH11 | Q8TC12 | 667 |
| RDH8 | RPE65 | Q16518 | 640 |
| RDH8 | LRAT | O95237 | 603 |
| RDH8 | PRPH2 | P23942 | 585 |
| RDH8 | SORD | Q00796 | 569 |
| RDH8 | RCVRN | P35243 | 457 |
| RDH8 | RBP3 | P10745 | 447 |
| RDH8 | RGR | P47804 | 442 |
| RDH8 | STRA6 | Q9BX79 | 416 |
| RDH8 | BCO1 | Q9HAY6 | 400 |
| RDH8 | RBP1 | P09455 | 399 |
| RDH8 | RBP4 | P02753 | 399 |
IntAct
3 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| PDGFA | LAMB1 | psi-mi:“MI:0914”(association) | 0.350 |
| RDH8 | CCT3 | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (9): RDH8 (Synthetic Lethality), RDH8 (Affinity Capture-MS), CAMK2B (Affinity Capture-MS), CCT3 (Affinity Capture-MS), CCT2 (Affinity Capture-MS), PPP2CA (Affinity Capture-MS), NBEA (Affinity Capture-MS), PPP2R5D (Affinity Capture-MS), PRAME (Affinity Capture-MS)
ESM2 similar proteins: A0A0H3KNE7, A0A3Q8GL18, A0A3Q8GLE8, A0A3Q8GYY4, A0A7N9VSG0, A0A7T8F1N2, A0A8F5XX49, A0A8I6GJ95, A0AAT9JA24, A5W4G5, A8C7R7, B8A5W4, D4A2B7, E9Q3D4, E9QUT3, G4N290, O35048, P0C622, P14061, P23102, P37440, P51656, P51661, P9WES5, P9WGQ2, P9WGQ3, Q08632, Q13268, Q17QU7, Q17QW3, Q4WR19, Q5C9I9, Q5R9W5, Q5SS80, Q7FAE1, Q7ZY31, Q8SPU8, Q8VBZ0, Q8XBJ4, Q91WL8
Diamond homologs: A0A017SE81, A0A0E3D8L9, A0A0U1LQE2, A0A140JWS5, A0A1U8QWA2, A0A5B8YU68, A0QYC2, A7IQF2, C0KTJ6, G0RH19, G4N286, G9N4A9, O16881, O55240, P05406, P0CU71, P0DKC7, P14061, P25970, P35731, P37694, P37959, P40471, P42317, P43713, P45200, P45375, P50160, P50203, P51658, P54554, P55006, P55336, P80873, Q04520, Q09851, Q0IH28, Q0VFE7, Q1QU27, Q1R183
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
28 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 1 |
| Likely pathogenic | 0 |
| Uncertain significance | 15 |
| Likely benign | 2 |
| Benign | 3 |
Top pathogenic / likely-pathogenic (1)
| Variant ID | HGVS | Classification |
|---|---|---|
| 3911902 | NM_015725.4(RDH8):c.262+1G>A | Pathogenic |
SpliceAI
1132 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 19:10013309:GATT:G | donor_gain | 1.0000 |
| 19:10017052:CGCAG:C | acceptor_loss | 1.0000 |
| 19:10017053:GCA:G | acceptor_loss | 1.0000 |
| 19:10017054:CAG:C | acceptor_loss | 1.0000 |
| 19:10017055:A:AG | acceptor_gain | 1.0000 |
| 19:10017055:A:G | acceptor_loss | 1.0000 |
| 19:10017055:AGTC:A | acceptor_gain | 1.0000 |
| 19:10017056:G:GA | acceptor_gain | 1.0000 |
| 19:10017056:GTC:G | acceptor_gain | 1.0000 |
| 19:10017056:GTCG:G | acceptor_gain | 1.0000 |
| 19:10017056:GTCGT:G | acceptor_gain | 1.0000 |
| 19:10017197:G:GT | donor_gain | 1.0000 |
| 19:10018729:A:AG | acceptor_gain | 1.0000 |
| 19:10018730:G:GG | acceptor_gain | 1.0000 |
| 19:10018730:GT:G | acceptor_gain | 1.0000 |
| 19:10018909:GG:G | donor_gain | 1.0000 |
| 19:10018910:GG:G | donor_gain | 1.0000 |
| 19:10020704:CACA:C | acceptor_loss | 1.0000 |
| 19:10020707:A:AC | acceptor_loss | 1.0000 |
| 19:10020707:A:AG | acceptor_gain | 1.0000 |
| 19:10020708:G:GG | acceptor_gain | 1.0000 |
| 19:10020708:GGT:G | acceptor_gain | 1.0000 |
| 19:10020803:G:GG | donor_gain | 1.0000 |
| 19:10021533:GGCC:G | acceptor_gain | 1.0000 |
| 19:10013599:GG:G | donor_gain | 0.9900 |
| 19:10013600:GG:G | donor_gain | 0.9900 |
| 19:10017047:T:TA | acceptor_gain | 0.9900 |
| 19:10017051:CCGCA:C | acceptor_loss | 0.9900 |
| 19:10017052:C:A | acceptor_gain | 0.9900 |
| 19:10017056:GT:G | acceptor_gain | 0.9900 |
AlphaMissense
1993 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 19:10018889:A:C | S141R | 0.992 |
| 19:10018891:C:A | S141R | 0.992 |
| 19:10018891:C:G | S141R | 0.992 |
| 19:10018892:A:C | S142R | 0.991 |
| 19:10018894:T:A | S142R | 0.991 |
| 19:10018894:T:G | S142R | 0.991 |
| 19:10020744:T:C | F160L | 0.991 |
| 19:10020746:C:A | F160L | 0.991 |
| 19:10020746:C:G | F160L | 0.991 |
| 19:10020739:C:T | S158F | 0.987 |
| 19:10020768:A:C | S168R | 0.985 |
| 19:10020770:C:A | S168R | 0.985 |
| 19:10020770:C:G | S168R | 0.985 |
| 19:10017063:C:A | A37D | 0.984 |
| 19:10020739:C:A | S158Y | 0.984 |
| 19:10020736:C:A | A157D | 0.982 |
| 19:10018858:G:C | K130N | 0.981 |
| 19:10018858:G:T | K130N | 0.981 |
| 19:10020748:C:A | A161D | 0.976 |
| 19:10018845:T:C | L126P | 0.975 |
| 19:10018890:G:T | S141I | 0.972 |
| 19:10013536:C:G | C13W | 0.971 |
| 19:10020792:T:C | F176L | 0.968 |
| 19:10020794:C:A | F176L | 0.968 |
| 19:10020794:C:G | F176L | 0.968 |
| 19:10018893:G:T | S142I | 0.966 |
| 19:10018810:C:A | N114K | 0.965 |
| 19:10018810:C:G | N114K | 0.965 |
| 19:10018854:T:C | M129T | 0.965 |
| 19:10018878:T:A | I137N | 0.965 |
dbSNP variants (sampled 300 via entrez): RS1000453173 (19:10013245 G>A,T), RS1001033567 (19:10012185 C>T), RS1001091759 (19:10016808 G>A,C), RS1001867320 (19:10012131 G>A), RS1002092963 (19:10018409 C>T), RS1002131807 (19:10014330 G>C), RS1002332372 (19:10016406 C>T), RS1002432945 (19:10014518 A>T), RS1002659975 (19:10021571 T>G), RS1003038855 (19:10014472 G>A), RS1003096895 (19:10019205 C>A,G,T), RS1003327109 (19:10011905 C>A,T), RS1003636477 (19:10019109 C>T), RS1003854234 (19:10020300 A>C), RS1004048109 (19:10022536 G>A)
Disease associations
OMIM: gene MIM:608575 | disease phenotypes: MIM:621259
GenCC curated gene-disease
Mondo (1): Stargardt disease 5 (MONDO:0980722)
Orphanet (0):
HPO phenotypes
10 total (10 of 10 shown, HPO-id order):
| HPO | Term |
|---|---|
| HP:0000007 | Autosomal recessive inheritance |
| HP:0000512 | Abnormal electroretinogram |
| HP:0000822 | Hypertension |
| HP:0003596 | Middle age onset |
| HP:0007722 | Retinal pigment epithelial atrophy |
| HP:0007906 | Ocular hypertension |
| HP:0012045 | Retinal flecks |
| HP:0031528 | Subretinal deposits |
| HP:0032037 | Mildly reduced visual acuity |
| HP:6000367 | Central thinning of the outer nuclear layer of the retina |
GWAS associations
1 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST002541_117 | Menarche (age at onset) | 2.000000e-13 |
EFO canonical traits (1, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0004703 | age at menarche |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
8 total (human), top 8 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| bisphenol F | decreases expression | 1 |
| abrine | increases expression | 1 |
| bisphenol S | decreases expression | 1 |
| Amiodarone | increases expression | 1 |
| Atrazine | increases expression | 1 |
| Benzo(a)pyrene | affects methylation | 1 |
| NADP | affects binding, increases activity | 1 |
| Silicon Dioxide | increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
- Disease cohort memberships (association, not causation — diseases whose associated-gene cohort lists this gene; a subset are also under Associated diseases): Stargardt disease 5